{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T02:58:18Z","timestamp":1772161098310,"version":"3.50.1"},"reference-count":45,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2008,12,1]],"date-time":"2008-12-01T00:00:00Z","timestamp":1228089600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1136\/ard.2008.097527","type":"journal-article","created":{"date-parts":[[2008,12,4]],"date-time":"2008-12-04T01:26:42Z","timestamp":1228354002000},"page":"1819-1826","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":101,"title":["Malignancies in the rheumatoid arthritis abatacept clinical development programme: an epidemiological assessment"],"prefix":"10.1016","volume":"68","author":[{"given":"T A","family":"Simon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A L","family":"Smitten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Franklin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Askling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Lacaille","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F","family":"Wolfe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M C","family":"Hochberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Suissa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1136\/ard.2008.097527_bib1","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1084\/jem.177.1.165","article-title":"Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7\/BB1","volume":"177","author":"Tan","year":"1993","journal-title":"J Exp Med"},{"key":"10.1136\/ard.2008.097527_bib2","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1056\/NEJMoa035075","article-title":"Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig","volume":"349","author":"Kremer","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2008.097527_bib3","doi-asserted-by":"crossref","first-page":"865","DOI":"10.7326\/0003-4819-144-12-200606200-00003","article-title":"Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial","volume":"144","author":"Kremer","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1136\/ard.2008.097527_bib4","doi-asserted-by":"crossref","unstructured":"Genant HK, Peterfy CG, Westhovens R. Abatacept inhibits structural damage progression in rheumatoid arthritis: results from the long-term extension of the AIM trial. Ann Rheum Dis 2008;67:1084\u20139.","DOI":"10.1136\/ard.2007.085084"},{"key":"10.1136\/ard.2008.097527_bib5","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1136\/ard.2007.074773","article-title":"Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-TNF therapy","volume":"67","author":"Genovese","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2008.097527_bib6","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies. Systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"key":"10.1136\/ard.2008.097527_bib7","unstructured":"Food and Drug Administration. Guidance for industry. Premarketing risk assessment. http:\/\/www.fda.gov\/CDER\/guidance\/6357fnl.htm (accessed 27 Dec 2006)."},{"key":"10.1136\/ard.2008.097527_bib8","doi-asserted-by":"crossref","unstructured":"Smitten AL, Simon TA, Hochberg MC. A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis Arthritis Res Ther 2008;10:R45.","DOI":"10.1186\/ar2404"},{"key":"10.1136\/ard.2008.097527_bib9","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1002\/art.21201","article-title":"Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase IIb, double-blind, randomized, placebo-controlled trial","volume":"52","author":"Kremer","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2008.097527_bib10","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1136\/ard.2006.055111","article-title":"Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial","volume":"66","author":"Weinblatt","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2008.097527_bib11","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa050524","article-title":"Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition","volume":"353","author":"Genovese","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2008.097527_bib12","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1002\/art.22070","article-title":"Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study","volume":"54","author":"Weinblatt","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2008.097527_bib13","doi-asserted-by":"crossref","unstructured":"Schiff M, Keiserman M, Codding C. Efficacy and safety of abatacept or infliximab versus placebo in ATTEST: a phase III, multicenter, randomized, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 2008;67:1096\u2013103.","DOI":"10.1136\/ard.2007.080002"},{"key":"10.1136\/ard.2008.097527_bib14","unstructured":"Schiff M, Pritchard C, Zhou X. The efficacy of abatacept in patients with active rheumatoid arthritis and an inadequate response to anti-TNF Therapy: the ARRIVE Trial. Arthritis Rheum 2007;56(suppl 9):S391; Abstract 942."},{"key":"10.1136\/ard.2008.097527_bib15","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1002\/art.22579","article-title":"The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation","volume":"56","author":"Wolfe","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2008.097527_bib16","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/art.21077","article-title":"Gaps in care for rheumatoid arthritis: a population study","volume":"53","author":"Lacaille","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2008.097527_bib17","unstructured":"Symmons DP, Silman AJ. The Norfolk Arthritis Register (NOAR). Clin Exp Rheumatol 2003;21(5 suppl 31):S94\u20139."},{"key":"10.1136\/ard.2008.097527_bib18","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1136\/ard.2005.045872","article-title":"Swedish registers to examine drug safety and clinical issues in RA","volume":"65","author":"Askling","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2008.097527_bib19","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1093\/qjmed\/91.6.445","article-title":"The General Practice Research Database. Scientific and Ethical Advisory Group","volume":"91","author":"Lawson","year":"1998","journal-title":"QJM"},{"key":"10.1136\/ard.2008.097527_bib20","unstructured":"National Cancer Institute. Surveillance, epidemiology and end results. http:\/\/seer.cancer.gov (accessed Dec 2008)."},{"key":"10.1136\/ard.2008.097527_bib21","doi-asserted-by":"crossref","unstructured":"Ab\u00e1solo L, J\u00fadez E, Descalzo MA, EMECAR Study Group. Cancer in rheumatoid arthritis: occurrence, mortality, and associated factors in a south European population. Semin Arthritis Rheum 2008;37:388\u201397.","DOI":"10.1016\/j.semarthrit.2007.08.006"},{"key":"10.1136\/ard.2008.097527_bib22","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/art.22430","article-title":"Influence of inflammatory polyarthritis on cancer incidence and survival","volume":"56","author":"Franklin","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2008.097527_bib23","first-page":"809","article-title":"Occurrence of neoplasia in patients with rheumatoid arthritis enrolled in a DMARD Registry","volume":"18","author":"Matteson","year":"1991","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2008.097527_bib24","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1002\/art.22864","article-title":"Biologic treatment of rheumatoid arthritis and the risk of malignancy","volume":"56","author":"Wolfe","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2008.097527_bib25","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/1097-0215(20001101)88:3<497::AID-IJC27>3.0.CO;2-J","article-title":"Risk of malignancy among patients with rheumatic conditions","volume":"88","author":"Thomas","year":"2000","journal-title":"Int J Cancer"},{"key":"10.1136\/ard.2008.097527_bib26","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1136\/ard.2004.033993","article-title":"Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists","volume":"64","author":"Askling","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2008.097527_bib27","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1002\/art.1780400906","article-title":"Rheumatoid arthritis and the risk of malignancy","volume":"40","author":"Cibere","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2008.097527_bib28","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/jnci\/85.4.307","article-title":"Incidence of cancer among patients with rheumatoid arthritis","volume":"85","author":"Gridley","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1136\/ard.2008.097527_bib29","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/0959-8049(96)00210-9","article-title":"Rheumatoid arthritis and cancer risk","volume":"32A","author":"Mellemkjaer","year":"1996","journal-title":"Eur J Cancer"},{"key":"10.1136\/ard.2008.097527_bib30","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3109\/03009749509099305","article-title":"The risk of cancer in rheumatoid arthritis patients in Japan","volume":"24","author":"Moritomo","year":"1995","journal-title":"Scand J Rheumatol"},{"key":"10.1136\/ard.2008.097527_bib31","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1002\/art.22056","article-title":"Tumor necrosis factor a antagonist use and cancer in patients with rheumatoid arthritis","volume":"54","author":"Setoguchi","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2008.097527_bib32","first-page":"551","article-title":"Low incidence of colorectal cancer in patients with rheumatoid arthritis","volume":"14","author":"Kauppi","year":"1996","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard.2008.097527_bib33","first-page":"1484","article-title":"Excess risk of lung cancer in patients with rheumatoid arthritis","volume":"23","author":"Kauppi","year":"1996","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2008.097527_bib34","first-page":"1850","article-title":"Adverse effects of low dose methotrexate therapy in rheumatoid arthritis","volume":"20","author":"McKendry","year":"1993","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2008.097527_bib35","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1136\/ard.2004.033241","article-title":"Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists","volume":"64","author":"Askling","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2008.097527_bib36","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1002\/art.10939","article-title":"Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relatives","volume":"48","author":"Ekstrom","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2008.097527_bib37","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1136\/ard.2005.044784","article-title":"Incidence of lymphoma in a large primary care derived cohort of cases of inflammatory polyarthritis","volume":"65","author":"Franklin","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2008.097527_bib38","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1136\/ard.2004.030528","article-title":"Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas","volume":"64","author":"Geborek","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2008.097527_bib39","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"10.1136\/ard.2008.097527_bib40","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.rdc.2004.01.007","article-title":"Associations between rheumatoid arthritis and malignancy","volume":"30","author":"Chakravarty","year":"2004","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1136\/ard.2008.097527_bib41","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1136\/ard.47.12.988","article-title":"Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20 year follow up study","volume":"47","author":"Silman","year":"1988","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2008.097527_bib42","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/art.21675","article-title":"Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis","volume":"54","author":"Baecklund","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2008.097527_bib43","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/S0049-0172(97)80023-6","article-title":"Lymphoma in patients with rheumatoid arthritis: association with the disease state or methotrexate treatment","volume":"26","author":"Georgescu","year":"1997","journal-title":"Semin Arthritis Rheum"},{"key":"10.1136\/ard.2008.097527_bib44","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V99.11.3909","article-title":"Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France","volume":"99","author":"Mariette","year":"2002","journal-title":"Blood"},{"key":"10.1136\/ard.2008.097527_bib45","unstructured":"Food and Drug Administration. Guidance for industry. Good pharmacovigilance practices and pharmacoepidemiologic assessment. http:\/\/www.fda.gov\/cber\/gdlns\/pharmacovig.htm (accessed 11 Jan 2007)."}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724215624?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724215624?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.2008.097527","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T08:49:19Z","timestamp":1739522959000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724215624"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":45,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["S0003496724215624"],"URL":"https:\/\/doi.org\/10.1136\/ard.2008.097527","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2009,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Malignancies in the rheumatoid arthritis abatacept clinical development programme: an epidemiological assessment","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.2008.097527","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 \u00a9 Simon et al 2009, Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}